How Long Does Rehab Last? — California Treatment Timeline Guide

By SoCal Addiction Centers Editorial Team | Last reviewed: | 16 min read Clinically Reviewed

Key Takeaways

  • Rehab duration depends on ASAM level of care, clinical severity, and continuing-care engagement, not a fixed program length. Detox runs 5–14 days. Residential runs 28–90+ days. IOP runs 8–12 weeks. Standard outpatient continues months to years. Typical total engagement across the continuum runs 6–12+ months for most substance-use disorders.
  • NIDA’s Principles of Drug Addiction Treatment consensus: “Remaining in treatment for an adequate period of time is critical,” with 90 days frequently cited as the minimum threshold below which outcomes decline meaningfully. Longer engagement correlates with better sustained-recovery outcomes.
  • California’s 1,501 DHCS-licensed SoCal SUD facilities operate at every ASAM level, from 5-day residential detox to months-long therapeutic community programs. Facility-offered program lengths do not always match clinical need; ask what the clinical justification is for the proposed length.
  • Post-acute withdrawal syndrome (PAWS) — residual withdrawal symptoms including sleep disturbance, mood instability, cognitive fog, anxiety — can persist weeks to months after acute withdrawal resolves. Treatment engagement during PAWS supports sustained recovery.
  • Insurance authorization frequently drives perceived “rehab length” in commercial-insurance contexts. Prior authorization and concurrent review produce pressure toward shorter stays than clinical guidelines would support. Parity appeals can extend authorization when medical necessity supports longer engagement.
  • Medi-Cal DMC-ODS at contracted California facilities provides zero-cost access to the full ASAM continuum. Length of stay is clinically determined rather than insurance-cap-driven.
  • “How long does rehab last” is the wrong framing. A better framing: “How long will continuing-care engagement be — across decreasing intensity — for sustained recovery?” Months-to-years across multiple levels of care is the honest answer for most clinically serious SUD.

How long does rehab last? — the honest answer

Rehab duration in California ranges from 5 days (short medical detox alone) to years (sustained outpatient and peer-support engagement) depending on the substance, clinical severity, co-occurring conditions, insurance structure, and individual response to treatment. The single-number answer people often want — “28 days,” “30 days,” “90 days” — reflects insurance-driven program-length conventions more than clinical evidence. NIDA’s Principles of Drug Addiction Treatment research consensus identifies treatment engagement of at least 90 days as the typical threshold below which outcomes decline meaningfully for substance-use disorder; longer engagement across decreasing-intensity care consistently correlates with better sustained-recovery outcomes.

This page walks through length-of-stay expectations at each ASAM level of care, the evidence base for why duration matters, the factors that push actual length of stay shorter or longer than clinical guidelines would indicate, and how California’s specific payer structures (DMC-ODS Medi-Cal, commercial insurance, self-pay) shape the duration conversation. Everything is grounded in publicly-published clinical guidance and California-specific data where available. We accept no referral fees from facilities.

Length of stay by ASAM level of care

The ASAM Criteria is the standard clinical framework for matching patients to appropriate levels of care. Each ASAM level has typical duration ranges, though individual cases vary substantially.

Withdrawal management (detox) levels

ASAM 1-WM — Ambulatory Withdrawal Management without Extended On-Site Monitoring — typically 5–10 days for alcohol and opioids; up to 2+ weeks for benzodiazepines. Patient returns home between appointments.

ASAM 2-WM — Ambulatory Withdrawal Management with Extended On-Site Monitoring — 5–10 days typical. More intensive than 1-WM; patient may spend extended hours at the clinic during peak symptom windows.

ASAM 3.2-WM — Clinically Managed Residential Withdrawal Management — 5–10 days for alcohol/opioid; 7–14 days for benzodiazepines. 24-hour non-medical supervision.

ASAM 3.7-WM — Medically Monitored Inpatient Withdrawal Management — 5–10 days for most substances; 7–14 days for benzos. 24-hour medical supervision.

ASAM 4.0-WM — Medically Managed Inpatient Withdrawal Management — hospital-based. Typically 3–7 days for acute medical stabilization, with step-down to residential or continuing care following.

Benzodiazepine tapers are the exception. Chronic benzo dependence typically requires extended tapering — weeks to months, occasionally longer — rather than the 5–10 day range typical for alcohol and opioid withdrawal. See our benzodiazepine addiction pillar.

Residential treatment levels

ASAM 3.1 — Clinically Managed Low-Intensity Residential — 30–180 days typical. Longer stays common in transitional housing and therapeutic community models.

ASAM 3.3 — Clinically Managed Population-Specific High-Intensity Residential — 30–90 days typical.

ASAM 3.5 — Clinically Managed High-Intensity Residential — 30–90 days typical. Most common “residential rehab” level in SoCal.

ASAM 3.7 — Medically Monitored Intensive Inpatient — 30–90 days typical; longer stays clinically supported in complex cases.

The “28-day residential program” — historically the dominant residential length in California and nationally — reflects mid-20th-century insurance convention more than clinical evidence. Modern clinical guidance typically supports longer stays (60–90+ days) for moderate-to-severe SUD when achievable.

Outpatient levels

ASAM 1.0 — Outpatient — ongoing, frequently months to years, with progressively decreasing intensity.

ASAM 2.1 — Intensive Outpatient (IOP) — 8–12 weeks typical; some programs structure as 3-month or 6-month engagements.

ASAM 2.5 — Partial Hospitalization (PHP) — 2–6 weeks typical; frequently a step-down from residential.

Continuing care and maintenance

Post-structured-program engagement through peer support, individual therapy, MAT continuation, and family involvement extends months to years for most patients. Clinical evidence supports the continuing-care continuum more than discrete-admission models; SAMHSA and ASAM guidance both emphasize long-term engagement.

Why treatment duration matters — the evidence

NIDA’s Principles of Drug Addiction Treatment — one of the most widely-cited research syntheses in addiction medicine — includes among its core consensus findings: “Remaining in treatment for an adequate period of time is critical. The appropriate duration for an individual depends on the type and degree of the patient’s problems and needs. Research indicates that most addicted individuals need at least 3 months in treatment to significantly reduce or stop their drug use and that the best outcomes occur with longer durations of treatment.”

This finding has been replicated across multiple research syntheses. SAMHSA’s TIP 45, SAMHSA’s TIP 42 on co-occurring disorders, and broad published outcome literature all converge on the length-is-critical consensus.

Specific findings that have emerged consistently:

  • Treatment engagement under 90 days shows meaningfully worse outcomes than 90+ days
  • Continuous engagement across decreasing intensity (residential → PHP → IOP → outpatient → peer support) outperforms single-admission residential with no follow-through
  • Relapse after short-duration residential without continuing-care step-down is common clinical observation
  • Longer engagement has diminishing marginal returns eventually, but meaningful returns extend well beyond the 90-day threshold

Specific effect-size percentages vary across studies and patient populations. The consistent signal is directional: longer engagement, better outcomes.

What drives actual length of stay in California

Clinically-indicated length of stay and actual length of stay often diverge. Several factors push actual LOS shorter or longer than clinical guidelines would indicate:

Insurance authorization and concurrent review

Commercial insurance authorizes residential treatment in short increments (typically 7–14 days initial, then concurrent review every few days). Carriers’ utilization management apply medical-necessity criteria that, post-SB 855, should align with ASAM. Pre-SB 855 and under ERISA self-funded plans, proprietary criteria sometimes produce pressure toward shorter stays than ASAM would support.

Denial and appeal: if carrier denies continued-stay authorization while ASAM continues to support residential, internal appeal and DMHC Independent Medical Review are the appropriate response. See our insurance coverage pillar for the appeal framework.

Medi-Cal DMC-ODS

Medi-Cal DMC-ODS authorization operates differently from commercial insurance. County assessment determines initial placement; continued-stay decisions happen within county behavioral health. Authorization is generally more flexible on length of stay when clinical justification supports it, though capacity constraints at contracted residential facilities produce their own access dynamics.

Medicare

Medicare Part A covers inpatient psychiatric hospitalization up to 190 days lifetime. For SUD specifically, Medicare Part A covers hospital-based care; Medicare Part B (and the 2024-added IOP benefit) covers outpatient. Length of stay is clinically determined within the 190-day lifetime cap.

Self-pay at commercial facilities

Self-pay patients have the most flexibility on length of stay because no insurance authorization constrains their access. Financial capacity becomes the primary driver; luxury and concierge facilities typically offer any length of stay the patient will fund.

Court-ordered treatment (drug court, Prop 36 of 2024, Laura’s Law AOT, probation-ordered treatment) typically specifies minimum engagement periods (frequently 12 months). These function as minimum LOS floors for the legal-compliance dimension, though clinical needs may extend engagement beyond the legally-required minimum.

Individual clinical response

Patient-specific factors — complexity of withdrawal, co-occurring conditions, treatment engagement, home environment, social support — drive meaningful variation. Some patients stabilize quickly and step down appropriately at earlier intervals; others require extended residential engagement to build sustained stability.

Family and logistical factors

Family support, employment obligations, housing stability, and dependent-care responsibilities all affect practical length of stay. A parent of young children may need a shorter residential stay because family logistics don’t accommodate extended residential; this may or may not align with clinical indication.

Post-acute withdrawal syndrome (PAWS) — the timeline after detox

Acute withdrawal resolves in 5–14 days for most substances. But post-acute withdrawal syndrome (PAWS) — residual physical and psychological symptoms — can persist weeks to months beyond acute withdrawal resolution. PAWS is not uniformly experienced but is clinically common, particularly for:

Opioid PAWS — typically 2–6 months; includes sleep disturbance, anxiety, dysphoria, cognitive fog, craving patterns.

Benzodiazepine PAWS — can be protracted; 6+ months in some patients, occasionally extending into years. Sometimes discussed under terminology “Benzodiazepine-Induced Neurological Dysfunction (BIND)” for protracted presentations.

Alcohol PAWS — typically 1–6 months; includes sleep disturbance, irritability, anxiety, protracted cognitive symptoms.

Stimulant PAWS — 1–3 months typical; anhedonia, fatigue, dysphoria, sleep disruption, concentration impairment.

Clinical implication: PAWS is a period of continued vulnerability to relapse. Treatment engagement during PAWS — at IOP, outpatient, or peer-support levels — supports sustained recovery through the vulnerability window. Facilities that discharge patients immediately at acute-withdrawal resolution and don’t address PAWS are providing clinically incomplete care.

Typical treatment continuum timeline

A typical sequential engagement across the continuum for a patient with moderate-to-severe SUD:

Weeks 1–2: Acute detox / withdrawal management (ASAM 3.2-WM or 3.7-WM) — 5–14 days depending on substance. Medical stabilization, medication initiation.

Weeks 2–6 or 2–12: Residential treatment (ASAM 3.5 or 3.7) — 28–90+ days. Behavioral treatment, medication stabilization, family engagement initiation, aftercare planning.

Weeks 6–12 (or months 2–3): Partial Hospitalization (ASAM 2.5) — 2–6 weeks. Step-down from residential, continuing clinical intensity while re-engaging with home environment.

Months 3–9: Intensive Outpatient (ASAM 2.1) — 8–12 weeks, sometimes 3–6 months. Continuing behavioral treatment with increasing patient autonomy.

Months 9–18+: Standard outpatient (ASAM 1.0) — months to indefinitely. Maintenance therapy, MAT continuation, psychiatric care continuity.

Continuing indefinitely: Peer support and self-management — AA, NA, SMART Recovery, Refuge Recovery, MBRP, or other modality of choice. Long-term MAT continuation where clinically indicated. Family support continuation.

Total typical engagement: 12–24+ months across the continuum for moderate-to-severe SUD. Shorter for mild cases; longer for complex polysubstance or dual-diagnosis cases.

When to stay longer, when to step down, when to step up

Duration decisions are clinical judgments made through ongoing ASAM assessment. General indicators:

Indicators supporting longer residential stay

  • Ongoing medical instability or withdrawal symptoms
  • Persistent psychiatric symptoms requiring integrated care
  • Unstable home environment making step-down unsafe
  • Prior rapid relapse after residential discharge
  • Recent substance use during residential stay
  • Incomplete skills development for lower-intensity care

Indicators supporting step-down

  • Stable medical and psychiatric presentation
  • Established skills and coping strategies
  • Stable housing and social support for lower-intensity engagement
  • Consistent treatment engagement pattern
  • Medication stabilization complete
  • Aftercare providers identified and first appointment scheduled

Indicators supporting step-up

  • New or worsening medical or psychiatric symptoms
  • Relapse or return to use during lower-intensity care
  • Loss of housing stability
  • Family crisis or support-system disruption
  • Treatment disengagement despite efforts to maintain

Step-up back to higher-intensity care is not a treatment “failure” — it is responsive clinical care. Insurance structures sometimes create barriers to step-up that should be addressed through appeals rather than forcing patients into clinically-inadequate care.

What facility-offered “program lengths” tell you

Many California facilities market specific program lengths — “30-day residential,” “60-day executive program,” “90-day therapeutic community.” These marketed lengths reflect facility operational structure more than clinical individualization. Honest facilities describe their typical length of stay but adjust individually based on clinical assessment.

Ask directly: “What is your typical length of stay? How is individual length of stay determined? What’s the clinical basis for recommending [specific length] for this patient’s situation?”

Facility responses to this question distinguish clinically-driven operations from insurance-authorization-driven operations. Both exist in California; the distinction matters for how you evaluate the program.

Medi-Cal DMC-ODS length of stay patterns

California’s Medi-Cal DMC-ODS coverage provides a useful reference point for clinically-driven (rather than commercial-insurance-driven) length of stay. DMC-ODS authorization is structured around ASAM criteria without the commercial-insurance concurrent-review pressure toward short stays. DMC-ODS residential authorizations typically run longer than commercial-insurance residential in comparable clinical situations.

This is not to say DMC-ODS length of stay is unlimited or that commercial insurance length of stay is clinically incorrect. It is to note that the different payer architectures produce different durations for reasons that are not primarily clinical — and that clinical guidelines (NIDA, ASAM, SAMHSA) support longer engagement than commercial insurance typically authorizes without appeal.

Medi-Cal DMC-ODS coverage detail is in our Medi-Cal pillar.

What patient-specific factors predict length of stay

Clinically-indicated length of stay varies by patient. The factors that most consistently predict longer engagement needs:

Substance and use pattern:

  • Opioid use disorder, particularly fentanyl-era: MAT continuation is typically indefinite rather than time-limited. Residential and IOP phases may be shorter than for other substances, but continuing-care engagement is extended.
  • Methamphetamine use disorder: longer residential engagement (60-90+ days) often clinically supported given no FDA-approved medication; contingency management during outpatient continuation.
  • Alcohol use disorder, severe: medical detox frequently longer (7-10 days), residential 60-90 days commonly indicated, protracted PAWS extends continuing care.
  • Benzodiazepine dependence: extended tapering timeline (months) means “rehab” duration is fundamentally different — the taper IS the treatment, rather than a pre-treatment phase.
  • Polysubstance use: combined withdrawal management and integrated treatment generally requires longer engagement than single-substance presentations.

Clinical severity indicators:

  • Prior treatment episodes — each prior episode typically indicates need for longer, more intensive current engagement
  • Psychiatric comorbidity severity — ASAM Dimension 3 scores of 3 or 4 typically support longer engagement
  • Medical comorbidity — liver disease, cardiovascular disease, HIV, chronic pain complicate and extend treatment
  • Recent overdose — particularly fentanyl overdose with resuscitation history — supports more intensive initial engagement
  • Prior withdrawal complications — seizure, DTs, or complicated detox history supports medical-level (3.7 or 4.0) detox

Social and environmental factors:

  • Housing instability — unhoused or unstably housed patients typically benefit from longer residential engagement given the treatment environment
  • Family dynamics — active using household or domestic violence makes step-down to home environment problematic
  • Employment demands — some patients need shorter residential with extended outpatient continuing care
  • Criminal justice involvement — court-mandated treatment typically specifies minimum duration floors

Individual response:

  • Engagement pattern — patients engaging strongly in residential may step down earlier; patients struggling with engagement often need extended residential
  • Craving and relapse indicators during residential — ongoing substance use during residential or strong craving patterns suggest need for continued higher intensity
  • Medication stabilization — some patients achieve MAT stabilization quickly; others require extended residential to find effective dosing and manage side effects

Clinical ASAM assessment integrates these factors into placement and length-of-stay recommendations. Individual patients will vary from “typical” in both directions.

What “successful completion” means and what follows

Rehab programs frequently frame successful completion as a graduation event — completion ceremony, certificate, celebration. This reflects the structured-program framing. Clinically, “successful completion” is better understood as achieving stabilization in the current level of care sufficient to step down to the next level — not as finishing treatment.

Immediate post-discharge from residential:

  • Medical stability — detox complete, medications stable, no acute medical issues
  • Psychiatric stability — active symptoms managed, suicidality or other safety concerns addressed
  • Skills baseline — patient has engaged with CBT, relapse prevention, and recovery-support modalities sufficiently to apply skills in outpatient setting
  • Continuing-care plan — specific next-level-of-care providers identified, first appointment scheduled, MAT prescriber confirmed
  • Housing plan — return to stable home environment, transition to recovery housing, or other structured housing arrangement
  • Family / support engagement — family members engaged with treatment process and aware of discharge plan

Year 1 of recovery (post-residential):

  • 2-6 weeks PHP, stepping to IOP
  • 8-12 weeks IOP, stepping to standard outpatient
  • Standard outpatient through the rest of year 1 with weekly or bi-weekly visits
  • Peer support engagement throughout (AA, SMART Recovery, Refuge Recovery, or other modality)
  • MAT continuation at appropriate intensity
  • Family therapy where clinically indicated
  • Psychiatric medication management for co-occurring conditions

Year 2 of recovery — continuing-care engagement continues at decreased intensity. Maintenance therapy, MAT continuation, peer support. Many patients remain in lower-intensity engagement indefinitely; this is clinically supported and associated with better sustained outcomes.

Beyond year 2 — recovery is a process rather than an endpoint. Life changes (relationships, employment, health conditions, family events) create vulnerability windows that may justify temporary intensity increase. The sustainable pattern is low-intensity ongoing engagement with responsive intensity adjustment as needed.

DMC-ODS length of stay in practice

California’s Medi-Cal DMC-ODS system provides clinically-driven (rather than commercial-insurance-constrained) length of stay reference. DMC-ODS authorization is structured around ASAM criteria. In practice:

  • Residential authorizations at DMC-ODS contracted facilities typically run longer than comparable commercial-insurance residential authorizations
  • Step-down decisions are clinically-driven; DMC-ODS does not apply concurrent-review pressure toward rapid step-down to the same extent commercial insurance does
  • Continuing-care access — DMC-ODS covers IOP, PHP, outpatient, and MAT without distinct length caps; engagement continues as clinically supported

This is not to say DMC-ODS length of stay is unlimited. Bed availability at contracted residential facilities creates access pressure in some counties. Individual facility program structures define practical length-of-stay patterns. But the payer architecture doesn’t impose the same short-stay pressure commercial insurance UM applies.

For commercial-insurance patients experiencing inappropriately short authorizations, the appropriate response is ASAM-based clinical documentation supporting continued stay and — where necessary — appeal through internal and external (DMHC IMR) processes.

Reframing the question

“How long does rehab last” is a reasonable question but often reflects an underlying assumption — that rehab is a discrete, time-bounded intervention that the patient “completes” and moves on from. That framing doesn’t match the clinical reality of substance-use disorder for most patients.

A more useful frame: how long will continuing-care engagement be — across decreasing intensity — for sustained recovery? Honest answer: months to years for most clinically serious SUD, with intensity decreasing over time and maintenance engagement continuing indefinitely. Discrete-admission framing captures the acute-treatment phase but understates the continuing-care framework that produces sustained outcomes.

Patients and families who approach treatment with continuing-care expectations generally fare better than those seeking discrete “rehab completion.” Some structure that supports long-term engagement — a primary outpatient therapist, MAT prescribing relationship, peer-support home group, family therapy resource — after residential discharge is clinically important.

Planning rehab duration for yourself or a family member?

Our editorial team can help you think through appropriate length of stay given clinical severity, insurance structure, and continuing-care planning. We do not accept referral fees from facilities. Calls are informational.

Contact our editorial team →

Use the Verify Insurance tool →

Need help now? Call (310) 596-1751 for editorial guidance.

Last reviewed: 2026-04-23. ASAM length-of-stay references reflect standard clinical guidance. NIDA and SAMHSA research references reflect established published consensus. Specific facility-level length-of-stay patterns vary. This page is editorial content, not medical advice.

Looking for treatment options in your area? We can help point you in the right direction. (310) 596-1751 — or request a callback.